
NCTN Genitourinary Cancer Trials Portfolio (Open as of 11/15/2025)


Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Genitourinary Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:



NCTN Genitourinary Cancer Trials (Open as of 11/15/2025)

	A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer
	with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene
H	Alterations
П	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
	A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell
П	Carcinoma with Bone Metastasis (RadiCal)
II	PREcision Diagnostics in Prostate Cancer Treatment (PREDICT)
	MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial
Ш	CaNcer
Ш	Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
Ш	Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
	GAIN-BCG: Gemcitabine Alternating with INtravesical BCG Randomized Against BCG Alone for Patients with Recurren
Ш	High Grade Non-Muscle Invasive Bladder Cancer
	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-
	Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Brachytherapy Boost
Ш	in Patients with Unfavorable Risk Localized Prostate Cancer (ASCENDE-SBRT)
	A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in
Ш	Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Ш	InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
	Phase III Study of Local or Systemic Therapy INtensification Directed by PET in Prostate CAncer Patients with Post-
Ш	ProstaTEctomy Biochemical Recurrence (INDICATE)
	A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelia
11/111	Cancer Prior to Nephroureterectomy
	A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in
Ш	Anti-PD(L)1-Resistant Advanced Urothelial Cancer
	Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients
Ш	with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*)
	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-
Ш	Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
	A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without
II	ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
	Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma
	(RCC) Receiving Immunotherapy (SAMURAI)
Ш	The Phase III `High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
	Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-
	Grade T1 Bladder Cancer (PARRC Trial)
Ш	The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive
Ш	Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
	Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for
111	Metastatic Renal Cell Carcinoma (PROBE Trial)
	A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care
	(Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1
Ш	Therapy Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atozolizumah (NSC#793609) in
11/111	Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in
11/111	Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) A Phase II Pandomized Trial of Cabazantinib (NEC #761069) with as Without Atazalizmanh (NEC #783609) in Patients
	A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients
11	with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
	A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations
"	A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate
III	Cancer (mCRPC), Stratified by Aggressive Variant Signature
1111	Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response
	, , , , , , , , , , , , , , , , , , , ,
	to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) Molecular Analysis for Combination Therapy Choice (ComboMATCH)
omer	Molecular Analysis for Combination Therapy Choice (ComboMATCH) A Pandomized Phase II Study of AMG 510 (Satorasib) with or Without Panitumumah in Advanced Solid Tumors: A
II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
	NAMES OF A STREET AND A STREET A
"	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor,